scPharmaceuticals’ (SCPH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $18.00 price target on the stock.

Separately, Craig Hallum reduced their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday.

scPharmaceuticals Stock Performance

Shares of NASDAQ SCPH opened at $3.46 on Thursday. The firm has a 50 day moving average price of $4.46 and a 200 day moving average price of $4.48. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.66 and a current ratio of 8.08. scPharmaceuticals has a 52-week low of $3.08 and a 52-week high of $6.71.

scPharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.44). The firm had revenue of $8.05 million for the quarter, compared to analyst estimates of $8.04 million. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. On average, sell-side analysts forecast that scPharmaceuticals will post -1.37 EPS for the current year.

Institutional Trading of scPharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of Montreal Can purchased a new position in shares of scPharmaceuticals in the 2nd quarter worth about $1,544,000. King Luther Capital Management Corp raised its holdings in shares of scPharmaceuticals by 51.8% during the 2nd quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock worth $9,592,000 after acquiring an additional 752,005 shares in the last quarter. Rice Hall James & Associates LLC increased its position in shares of scPharmaceuticals by 76.9% during the 2nd quarter. Rice Hall James & Associates LLC now owns 497,227 shares of the company’s stock valued at $2,163,000 after purchasing an additional 216,122 shares during the last quarter. AIGH Capital Management LLC grew its position in shares of scPharmaceuticals by 3.4% during the 2nd quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock worth $15,244,000 after buying an additional 115,206 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of scPharmaceuticals by 266.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 72,692 shares of the company’s stock worth $316,000 after purchasing an additional 52,870 shares during the last quarter. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.